US FDA approves Ionis Pharma's genetic disorder drug
Adds analyst comments in paragraph 12 and 13
By Mariam Sunny and Kamal Choudhury
Dec 19 (Reuters) -The U.S. Food and Drug Administration has approved Ionis Pharmaceuticals' IONS.O drug to treat a rare genetic disorder, making it the company's first wholly-owned drug, the health regulator's website showed on Thursday.
The drug, chemically known as olezarsen and branded as Tryngolza, is also the first approved treatment for familial chylomicronemia syndrome (FCS), a disorder that prevents the body from breaking down fats and is characterized by extremely high levels of triglycerides.
FCS is caused by the deficiency or impaired function of the lipoprotein lipase enzyme, responsible for breaking down triglycerides — which lead to inflammation of the pancreas when accumulated in the blood.
A strict low-fat diet is the current first-line treatment for the condition.
The drug was approved as an add-on treatment to diet to reduce triglycerides in adults with the condition.
The disorder affects fewer than 5,000 people in the U.S., according to government data.
"We don't see any hurdles on supply. We have manufactured and (are) ready to go," CEO Brett Monia told Reuters ahead of the approval.
"We will be planning to price olezarsen as you would, a first-time treatment for a severe, rare disease," Monia said.
The company said it will announce details on the drug's pricing in an investor conference call.
Ionis' application for the drug was based on data from a late-stage study in which it helped reduce triglyceride levels by 44% in patients, compared to a placebo.
Patients are still required to follow recommended dietary restrictions, Monia said.
Given the low prevalence of the disease, and entry of rival drug by the second half of next year, BMO Capital Markets analyst Kostas Biliouris does not expect FCS to be a significant opportunity for the company.
Biliouris estimates peak sales of $341 million in FCS.
The company has partnered with several major drugmakers such as Biogen BIIB.O and Swiss-based Novartis NOVN.S to develop other treatments.
Reporting by Sriparna Roy, Kamal Choudhury and Mariam Sunny in Bengaluru; Editing by Shailesh Kuber and Alan Barona
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
